GlassScriptPhysician profile
Paul C Copeland
NPI 1477667152
$901.54
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $307 · 2021: $341.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $301.13 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.42 | 2020-2021 | |
| Adlon Therapeutics L.P. | $95.77 | 2020-2021 | |
| Tris Pharma INC | $83.84 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $67.86 | 2021 | |
| Lundbeck LLC | $42.45 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $39.76 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.73 | 2019 | |
| Ironshore Pharmaceuticals INC. | $28.22 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.23 | 2021 | |
| Avanir Pharmaceuticals, INC. | $22.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.